GlassScriptPhysician profile
Nellie N Plummer
NPI 1568717023
$2,779.90
in general payments reported to CMS, 2019-2025
25 companies · $679 in 2025
The $679 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $212 · 2021: $354 · 2022: $275 · 2023: $214 · 2024: $512 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $557.03 | 2019-2025 | Rocklatan, Eysuvis, Centurion |
| Bausch & Lomb Americas INC. | $433.62 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $328.53 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $205.65 | 2019-2021 | |
| Allergan, INC. | $144.58 | 2019-2021 | |
| Shire North American Group INC | $122.02 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $115.95 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $108.99 | 2025 | Vevye |
| Amgen INC. | $86.64 | 2024-2025 | Tepezza |
| Rxsight INC | $85.83 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $82.40 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $68.01 | 2021-2022 | |
| Tearlab Corp | $60.57 | 2020 | |
| Sun Pharmaceutical Industries INC. | $48.87 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $45.42 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $44.17 | 2022-2023 | Iyuzeh |
| Abbvie INC. | $39.30 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $38.77 | 2019 | |
| Ivantis, INC | $37.91 | 2021 | |
| Beaver-Visitec International, INC. | $28.49 | 2025 | |
| Mallinckrodt Hospital Products INC. | $22.44 | 2024 | Acthar |
| Oyster Point Pharma, INC. | $22.37 | 2022 | |
| Biotissue Holdings INC. | $20.12 | 2020 | |
| Eyepoint US, INC. | $16.48 | 2019 | |
| Sight Sciences, INC. | $15.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nellie Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.